Search Medical Condition
Please enter condition
Please choose location

Bath, United Kingdom Clinical Trials

A listing of Bath, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (36) clinical trials

STAMPEDE: Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy: A Multi-Stage Multi-Arm Randomised Controlled Trial

STAMPEDE (also known as MRC PR08) is a multi-arm multi-stage (MAMS) randomised controlled trial recruiting in the UK and Switzerland. It aims to evaluate multiple therapeutic strategies in the management of high-risk locally advanced and metastatic hormone-naïve prostate cancer. Each novel treatment strategy is compared against a single, contemporaneous control ...

Phase

0.0 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

0.0 miles

Learn More »

An Observational Study of Presentation Treatment Patterns and Outcomes in Multiple Myeloma Participants

This is a non-interventional, observational. This study will look at contemporary, real-world presentation, therapies, and clinical outcomes in participants with MM. Participants will not be asked to change their routine clinical treatment. Participants will have to complete a patient self-reported outcomes (PROs) survey at home or during routine visits. The ...

Phase N/A

0.0 miles

Learn More »

Olaparib +/- Cediranib or Chemotherapy in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer

Olaparib is a PARP inhibitor which targets BRCA1/2 mutated tumour cells and cediranib is an anti-angiogenic drug which reduces blood supply to the tumour, suppressing tumour viability. Phase I/II trials of both drugs have shown these are well tolerated alone or in combination in ovarian cancer. The trial aims to ...

Phase

0.0 miles

Learn More »

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Chlorambucil (Chl) has been the mainstay of CLL treatment for half a century. However, frontline treatment has improved considerably over the last decade, first by the advent of fludarabine plus cyclophosphamide (FC), and more recently by the addition of the anti-CD20 antibody, rituximab, to FC. Although FC-based regimens are considerably ...

Phase

0.0 miles

Learn More »

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

The incidence of DLBCL is increasing and with an expanding elderly population, the incidence will continue to rise. Given that about 40% of cases of DLBCL occur in patients aged over 70 and the number of co-mobilities increases with age, research to investigate the optimal treatment of DLBCL in this ...

Phase

0.0 miles

Learn More »

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage) Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

This multicenter study uses a randomized, double-blind, placebo-controlled, parallel-group design. A screening period (SCR) running up to 10 weeks before randomization will be used to assess subject eligibility followed by 104 weeks of treatment. At BSL approximately 990 subjects whose eligibility is confirmed will be randomized to one of four ...

Phase

0.46 miles

Learn More »

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis

This is a prospective, observational, cohort study to collect data on adult participants who have a confirmed diagnosis of psoriatic arthritis (PsA) and are starting either STELARA or a new TNFi as a new therapy in a first, second, or third line of biologic disease-modifying antirheumatic drug (bDMARD) therapy. Approximately ...

Phase N/A

0.46 miles

Learn More »